Thrombolysis for Acute Stroke in Routine Clinical Practice
Open Access
- 23 September 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (17) , 1994-2001
- https://doi.org/10.1001/archinte.162.17.1994
Abstract
ACUTE ISCHEMIC STROKE is a major medical problem in the United States, where approximately 600 000 new events occur each year. Although few specific treatment options exist, thrombolytic therapy with tissue plasminogen activator (tPA) improved neurological outcomes in a randomized controlled trial.1,2 The beneficial effects of tPA therapy appear to be long lasting2 and cost-effective,3 and thrombolytic therapy is now part of nearly every treatment guideline and consensus statement for acute ischemic stroke.4 Despite these recommendations regarding the use of thrombolytic therapy, only a minority of eligible patients are treated with tPA,5,6 and national efforts are under way to increase the use of tPA.This publication has 2 references indexed in Scilit:
- Effects of tissue plasminogen activator for acute ischemic stroke at one yearJournal of Neurosurgical Anesthesiology, 1999
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997